ASO Author Reflections: Characteristics of Surgery for Biliary Tract Cancer that Should be Considered During the Design of Future Clinical Trials

Affiliations

¹ Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. shkobaya@east.ncc.go.jp.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
³ Department of Medical Oncology, Tochigi Cancer Center, Tochigi, Japan.
⁴ Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
⁵ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁶ Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁷ Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
⁸ Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
⁹ Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
¹⁰ Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.

Comment

Shin Kobayashi et al. Ann Surg Oncol. 2023 Nov.

. 2023 Nov;30(12):7384-7385.

doi: 10.1245/s10434-023-13922-5. Epub 2023 Jul 13.

¹ Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. shkobaya@east.ncc.go.jp.
² Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
³ Department of Medical Oncology, Tochigi Cancer Center, Tochigi, Japan.
⁴ Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
⁵ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁶ Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
⁷ Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
⁸ Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
⁹ Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
¹⁰ Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.

No abstract available

Comment on

A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S, Ikeda M, Nakachi K, Ueno M, Okusaka T, Todaka A, Satoi S, Tomokuni A, Konishi M, Furuse J. Kobayashi S, et al. Ann Surg Oncol. 2023 Nov;30(12):7331-7337. doi: 10.1245/s10434-023-13913-6. Epub 2023 Jul 14. Ann Surg Oncol. 2023. PMID: 37450093

1. Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195–203. https://doi.org/10.1016/S0140-6736(22)02038-4 . - DOI - PubMed
1. Kobayashi S, Ikeda M, Nakachi K, et al. A multicenter survey on eligibility for a randomized, phase III trial of adjuvant chemotherapy for resected biliary tract cancer (JCOG1202, ASCOT). Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13913-6 - DOI - PubMed - PMC